Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
bluebird bio (BLUE)
NASDAQ:BLUE
Bluebird Bio (BLUE) Stock Price & Analysis
2,528 Followers
BLUE Stock Chart & Stats
Day’s Range$0.91 - $1.02
52-Week Range― - ―
Previous Close$0.97
Volume6.55M
Average Volume (3M)N/A
Market Cap
$177.90M
Enterprise Value$316.49M
Total Cash (Recent Filing)$174.29M
Total Debt (Recent Filing)$303.71M
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
-$0.44Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding109,336,211
10 Day Avg. Volume6,024,867
30 Day Avg. Volume6,648,228
Standard Deviation0.21
R-Squared0.04
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.49
Price to Sales (P/S)29.50
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.05
Enterprise Value/Gross Profit-48.84
Enterprise Value/Ebitda-3.63
Forecast
1Y Price Target
$3.67Price Target Upside297.62% Upside
Rating ConsensusHold
Number of Analyst Covering11
Bluebird Bio News
PremiumStock Analysis & Ideas
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
PremiumStock Analysis & Ideas
Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game?
Bulls Say, Bears Say
Bulls Say
Financial HealthBLUE expects cash and equivalents to fund operations through the first quarter of 2026.
Market Access ExpansionBLUE has signed its first Medicaid outcomes-based agreement and is engaged with more than 15 Medicaid agencies.
Product DemandDemand for Zynteglo and Skysona continues to grow, with expectations of a steady uptick in utilization.
Bears Say
Financial PerformanceRevenue of $7.8mm was below estimates of $21.5mm/$18.8mm, indicating a significant shortfall in financial expectations.
Financial ReportingThe restatement of 2022/23 financials for treatment of leases has undermined investor confidence in the company's financial integrity.
Product LaunchLaunch in the SCD market is not gaining the anticipated traction, casting doubts over the company's ability to meet its patient start targets.
---
Ownership Overview
4.95% Insiders
10.43% Mutual Funds
11.08% Other Institutional Investors
73.54% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLUE FAQ
What was bluebird bio’s price range in the past 12 months?
Currently, no data Available
What is bluebird bio’s market cap?
Currently, no data Available
When is bluebird bio’s upcoming earnings report date?
bluebird bio’s upcoming earnings report date is May 02, 2024 which is in 7 days.
How were bluebird bio’s earnings last quarter?
bluebird bio released its earnings results on Mar 26, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.662 by $0.072.
Is bluebird bio overvalued?
According to Wall Street analysts bluebird bio’s price is currently Undervalued.
Does bluebird bio pay dividends?
bluebird bio pays a Notavailable dividend of $8.88 which represents an annual dividend yield of N/A. See more information on bluebird bio dividends here
What is bluebird bio’s EPS estimate?
bluebird bio’s EPS estimate is -$0.44.
How many shares outstanding does bluebird bio have?
Currently, no data Available
What happened to bluebird bio’s price movement after its last earnings report?
bluebird bio reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.662. Following the earnings report the stock price went down -11.765%.
Which hedge fund is a major shareholder of bluebird bio?
Among the largest hedge funds holding bluebird bio’s share is Farallon Capital Management, L.L.C.. It holds bluebird bio’s shares valued at 3M.
---
Bluebird Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.67 (297.62% Upside)
$3.67 (297.62% Upside)
Blogger Sentiment
Bullish
BLUE Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 925.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $35.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
---
BLUE Company Deck
---
BLUE Earnings Call
Q4 2024
0:00 / 0:00
---
BLUE Stock 12 Months Forecast
Average Price Target
$3.67
▲(297.62% Upside)
Technical Analysis
Sarepta Therapeutics
―
Ionis Pharmaceuticals
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Best Analysts Covering BLUE
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+46.97%
reiterated a buy rating last month
Copying Gena Wang's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +46.97% per trade.
---